CVS Health (CVS) PT Set at $77.00 by Citigroup

CVS Health (NYSE:CVS) received a $77.00 target price from equities research analysts at Citigroup in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has a “neutral” rating on the pharmacy operator’s stock. Citigroup’s price target suggests a potential upside of 9.83% from the stock’s current price.

A number of other analysts have also issued reports on the stock. Robert W. Baird reiterated a “hold” rating and set a $77.00 price objective on shares of CVS Health in a research note on Friday, October 27th. Needham & Company LLC upgraded shares of CVS Health from a “hold” rating to a “buy” rating and lifted their price target for the stock from $69.02 to $79.00 in a research note on Friday, November 10th. Deutsche Bank restated a “hold” rating on shares of CVS Health in a research note on Tuesday, December 5th. Mizuho set a $90.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research note on Tuesday, October 24th. Finally, Raymond James Financial restated a “buy” rating on shares of CVS Health in a research note on Monday, December 4th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $87.82.

CVS Health (NYSE CVS) traded up $0.24 on Tuesday, hitting $70.11. 8,796,114 shares of the stock were exchanged, compared to its average volume of 9,260,000. The stock has a market capitalization of $71,020.00, a price-to-earnings ratio of 11.88, a P/E/G ratio of 1.16 and a beta of 0.92. CVS Health has a 12 month low of $66.45 and a 12 month high of $84.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. The company had revenue of $48.39 billion for the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.71 earnings per share. analysts forecast that CVS Health will post 6.47 earnings per share for the current year.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of CVS Health stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares of the company’s stock, valued at $1,166,700. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.61% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Formidable Asset Management LLC boosted its holdings in shares of CVS Health by 871.3% during the fourth quarter. Formidable Asset Management LLC now owns 14,666 shares of the pharmacy operator’s stock valued at $1,063,000 after acquiring an additional 13,156 shares during the period. Renaissance Technologies LLC acquired a new position in shares of CVS Health during the fourth quarter valued at $136,931,000. Kiltearn Partners LLP boosted its holdings in shares of CVS Health by 52.0% during the fourth quarter. Kiltearn Partners LLP now owns 3,139,995 shares of the pharmacy operator’s stock valued at $227,650,000 after acquiring an additional 1,074,795 shares during the period. Merit Financial Group LLC acquired a new position in shares of CVS Health during the fourth quarter valued at $277,000. Finally, Focused Wealth Management Inc boosted its holdings in shares of CVS Health by 90.5% during the fourth quarter. Focused Wealth Management Inc now owns 1,781 shares of the pharmacy operator’s stock valued at $129,000 after acquiring an additional 846 shares during the period. 80.81% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/13/cvs-health-cvs-pt-set-at-77-00-by-citigroup.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply